2006
Gastric bypass reduces biochemical cardiac risk factors
Williams DB, Hagedorn JC, Lawson EH, Galanko JA, Safadi BY, Curet MJ, Morton JM. Gastric bypass reduces biochemical cardiac risk factors. Surgery For Obesity And Related Diseases 2006, 3: 8-13. PMID: 17196442, DOI: 10.1016/j.soard.2006.10.003.Peer-Reviewed Original ResearchConceptsCardiac risk factorsHDL cholesterol ratioCoronary artery diseaseC-reactive proteinTotal cholesterol/HDL cholesterol ratioCholesterol/HDL cholesterol ratioHigh-sensitivity C-reactive proteinTriglyceride/HDL cholesterol ratioGastric bypassRisk factorsCholesterol ratioMumol/LLipoprotein cholesterolTotal cholesterolBiochemical markersHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMean body mass indexGastric bypass patientsLipid-lowering medicationsPreventable risk factorsBody mass indexCertain biochemical markersSingle academic institutionCause of death
2005
A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol
Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK. A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. Clinical Cancer Research 2005, 11: 3836-3845. PMID: 15897584, DOI: 10.1158/1078-0432.ccr-04-2651.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBilirubinCamptothecinCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p21Drug Administration ScheduleDrug InteractionsFemaleFlavonoidsHumansIntracellular Signaling Peptides and ProteinsIrinotecanMaleMaximum Tolerated DoseMiddle AgedNeoplasmsPiperidinesTreatment OutcomeTumor Suppressor Protein p53ConceptsCombination therapyCycle 1 dose-limiting toxicitiesPhase I clinical trialDose-limiting diarrheaPhase II dosePosttreatment tumor biopsiesSignificant pharmacokinetic interactionsAdvanced solid tumorsDose-limiting toxicityPhase I trialBaseline serum bilirubinColorectal cancer xenograftsWild-type p53 tumorsMumol/LBaseline bilirubinFlavopiridol concentrationsStable diseasePartial responseI trialPharmacokinetic interactionsSerum bilirubinDifferentiation-related gene-1Responsive diseaseHepatocellular cancerCancer xenografts
1996
In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate.
Yoshida D, Piepmeier J, Teramoto A. In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate. Neurosurgery 1996, 39: 360-6. PMID: 8832674, DOI: 10.1097/00006123-199608000-00025.Peer-Reviewed Original ResearchConceptsEstramustine phosphateMumol/LGlioblastoma cell linesCell proliferationRelative survival ratesTreatment of glioblastomaCell linesTime-dependent depressionAnti-invasive abilityDevelopment of agentsHuman glioblastoma cell linesU87MG human glioblastoma cellsHuman glioblastoma cellsSurvival rateTumor proliferationDrug concentrationsMonotetrazolium assayAntiproliferative capacityCell invasivenessGlioblastoma cellsNon-DNA targetsBasement membraneInvasion indexInvasive potentialSelective antiproliferative activityHyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole.
Alappan R, Perazella M, Buller G. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Annals Of Internal Medicine 1996, 124: 316-20. PMID: 8554227, DOI: 10.7326/0003-4819-124-3-199602010-00006.Peer-Reviewed Original ResearchConceptsSerum potassium concentrationSerum creatinine levelsMumol/LBlood urea nitrogen levelsPeak potassium concentrationTrimethoprim-sulfamethoxazole therapyCreatinine levelsUrea nitrogen levelsTrimethoprim-sulfamethoxazoleTreatment groupsPotassium concentrationControl groupCommunity-based teaching hospitalDevelopment of hyperkalemiaDays of therapyProspective chart reviewConcurrent renal insufficiencyRenal insufficiencyChart reviewSevere hyperkalemiaHospitalized patientsSerum sodiumTeaching hospitalAnion gapPatients
1993
Increased Mortality Associated With Vitamin A Deficiency During Human Immunodeficiency Virus Type 1 Infection
Semba R, Graham N, Caiaffa W, Margolick J, Clement L, Vlahov D. Increased Mortality Associated With Vitamin A Deficiency During Human Immunodeficiency Virus Type 1 Infection. JAMA Internal Medicine 1993, 153: 2149-2154. PMID: 8379807, DOI: 10.1001/archinte.1993.00410180103012.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 (HIV-1) infectionHIV-1-seropositive individualsVirus type 1 infectionCD4 T cellsHIV-1 infectionType 1 infectionPlasma vitaminT cellsHIV-1-seronegative individualsMean plasma vitaminLow CD4 levelsIntravenous drug usersHIV-seropositive participantsBlood cell countImportant risk factorNormal immune functionMumol/LCD4 levelsSeronegative individualsImmunologic statusSerologic markersClinical outcomesLiver diseaseSeropositive individualsIncreased Mortality
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply